Anika Therapeutics, Inc.
ANIK
$21.38
$0.703.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.33% | -0.67% | -5.91% | 30.55% | 16.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.33% | -0.67% | -5.91% | 30.55% | 16.51% |
| Cost of Revenue | -5.61% | 7.59% | 13.18% | 124.11% | 71.92% |
| Gross Profit | 13.33% | -5.79% | -16.71% | -2.41% | -5.70% |
| SG&A Expenses | 0.62% | -1.92% | -11.64% | 68.73% | 25.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.18% | 2.92% | -0.43% | 86.40% | 43.92% |
| Operating Income | 68.05% | -70.04% | -145.85% | -160.31% | -167.99% |
| Income Before Tax | 61.01% | -117.35% | -236.72% | -144.63% | -149.44% |
| Income Tax Expenses | -96.19% | -86.61% | -88.92% | -66.37% | -45.11% |
| Earnings from Continuing Operations | 75.87% | -2.28% | -13.04% | -244.31% | -350.94% |
| Earnings from Discontinued Operations | 98.61% | 100.03% | 98.11% | 33.38% | -45,319.05% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.76% | 80.50% | 80.70% | 66.12% | 18.27% |
| EBIT | 68.05% | -70.04% | -145.85% | -160.31% | -167.99% |
| EBITDA | 168.07% | -398.86% | -558.59% | -132.66% | -127.68% |
| EPS Basic | 93.57% | 79.57% | 80.25% | 65.67% | 18.14% |
| Normalized Basic EPS | 93.97% | -115.55% | -345.16% | -144.32% | -146.56% |
| EPS Diluted | 93.27% | 79.28% | 79.86% | 65.52% | 17.95% |
| Normalized Diluted EPS | 91.79% | -114.99% | -344.07% | -144.12% | -146.28% |
| Average Basic Shares Outstanding | -4.23% | -3.24% | -2.60% | -2.21% | -1.40% |
| Average Diluted Shares Outstanding | -3.21% | -2.41% | -1.77% | -1.90% | -1.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |